Biology of Human Primary Bone Marrow Mesenchymal Stromal Stem Cells

Ghazanfari, Roshanak

2017

Link to publication

Citation for published version (APA):

Total number of authors:
1

General rights
Unless other specific re-use rights are stated the following general rights apply:
Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.
• Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
• You may not further distribute the material or use it for any profit-making activity or commercial gain
• You may freely distribute the URL identifying the publication in the public portal

Read more about Creative commons licenses: https://creativecommons.org/licenses/

Take down policy
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.
Human bone marrow contains a population of non-hematopoietic stromal stem/progenitor cells (BMSCs), which play a central role for bone marrow stroma and the hematopoietic microenvironment. However, the precise characteristics and potential stem cell properties of defined BMSC populations have not yet been thoroughly investigated. Using standard adherent colony-forming unit fibroblast (CFU-F) assays, we have previously shown that BMSCs were highly enriched in the nonhematopoietic CD271pos/CD140alow/neg fraction of normal adult human bone marrow. In this study, we demonstrate that prospectively isolated CD271pos/CD140alow/neg BMSCs expressed high levels of hematopoiesis supporting genes and signature mesenchymal and multipotency genes on a single cell basis. Furthermore, CD271pos/CD140alow/neg BMSCs gave rise to non-adherent sphere colonies (mesenspheres) with typical surface marker profile and trilineage in vitro differentiation potential. Importantly, serial transplantations of CD271pos/CD140alow/neg BMSC-derived mesenspheres (single cell and bulk) into immunodeficient NOD scid gamma (NSG) mice showed increased mesensphere numbers and full differentiation potential after both primary and secondary transplantations. In contrast, BMSC self-renewal potential decreased under standard adherent culture conditions. These data therefore indicate that CD271pos/CD140alow/neg BMSCs represent a population of primary stem cells with MSC phenotype and sphere-forming capacity that fulfill stringent functional stem cell criteria in vivo in a serial transplantation setting.

Keywords: bone marrow stromal cells, stem cells, BMSC, mesenspheres, self-renewal, serial transplantation

Introduction

Human bone marrow contains a population of non-hematopoietic stromal stem/progenitor cells (BMSCs), which are important components of the hematopoietic stem cell niche, give rise to the hematopoietic stroma upon transplantation, and possess in vivo multilineage differentiation capacities toward skeletal lineages [1–3]. Despite their key role in bone marrow physiology, little is known about BMSC stem cell characteristics, which is mainly due to the fact that primary BMSCs have thus far been elusive for a precise phenotypical definition. However, recent progress has led to the identification of suitable markers/marker combinations to effectively enrich BMSCs [1,2,4–6], and furthermore, recently-developed non-adherent mesenchyme cultures allowed to assay and amplify potent hematopoiesis-supporting BMSCs while preserving their undifferentiated phenotype [7].

Using these tools, the current study therefore aimed to investigate key phenotypical and, importantly, functional stem cell properties of prospectively isolated human BMSCs. Our results clearly demonstrate for the first time that non-hematopoietic CD271pos/CD140alow/neg cells are stromal stem cells with in vivo self-renewal and differentiation potential in a serial transplantation setting.

Materials and Methods

Bone marrow mononuclear cells

In total, bone marrow samples (60 mL) were aspirated from the iliac crest bone of consenting healthy adult donors (n = 41, median age 25 years, and range 19–35). The study was approved by the local ethics committee. Bone marrow mononuclear cells (BM-MNCs) were isolated by density gradient centrifugation (Ficoll-Paque Premium; GE Healthcare Life Sciences) following incubation with RosetteSep Human Mesenchymal Stem Cell Enrichment Cocktail (StemCell Technologies) for lineage depletion (CD3, CD14, CD19, CD38, CD66b, and glycoporphin A).

1Lund Stem Cell Center, University of Lund, Lund, Sweden.
2Division of Molecular Hematology, Department of Laboratory Medicine, University of Lund, Lund, Sweden.
3Department of Hematology, Skåne University Hospital, Lund, Sweden.

© Roshanak Ghazanfari et al., 2016; Published by Mary Ann Liebert, Inc. This Open Access article is distributed under the terms of the Creative Commons Attribution Noncommercial License (http://creativecommons.org/licenses/by-nc/4.0/) which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and the source are credited.
Lineage-depleted BM-MNCs were incubated in blocking buffer [DPBS w/o Ca\(^{2+}\), Mg\(^{2+}\), 3.3 mg/mL human normal immunoglobulin (Octapharma)] and 1% fetal bovine serum (Life Technologies), followed by staining with monoclonal antibodies against CD45, CD271, and CD140a (for detailed information on the antibodies used in this study, please see Supplementary Materials and Methods; Supplementary Data are available online at www.liebertpub.com/scd). Sorting gates were set according to the corresponding fluorescence-minus-one (FMO) controls. Cells were sorted on a fluorescence activated cell sorting (FACS) Aria II or a FACS Aria III cell sorter (BD Biosciences). Dead cells were excluded by 7-amino-actinomycin (7-AAD; Sigma) staining, and doublets were excluded by gating on FSC-H versus FSC-W and SSC-H versus SSC-W. A description of the flow cytometric analysis is provided in the Supplementary Materials and Methods.

Non-adherent mesensphere cultures

Sorted BM-MNCs were plated at low density (<1,000 cells/cm\(^2\)) in ultralow adherence plates (Corning) in sphere growth medium as described before [8]. The medium composition is described in detail in the Supplementary Materials and Methods. To prevent cell aggregation, cultures were left untouched for 1 week. Thereafter, half-medium changes were performed twice weekly. Spheres were passaged following enzymatic digestion with 0.25% type I collagenase (StemCell Technologies) for 30 min at 37\(^{\circ}\)C, followed by washing with PBS, and replating at clonal density.

Generation of adherent marrow stromal cells and forming unit fibroblast assays

Sorted BM-MNCs were cultured in standard MSC culture medium [StemMACS MSC Expansion Medium (Miltenyi Biotec, Bergisch Gladbach) plus 1% antibiotic-antimycotic solution (Sigma)]. Medium was changed weekly and passaged as described [2]. Colony-forming unit fibroblast (CFU-F) assays were performed as before [2] and as described in the Supplementary Materials and Methods.

In vitro differentiation assays

Stromal cells derived from adherent and sphere cultures were differentiated toward the adipogenic, osteogenic, and chondrogenic lineages as described [2]. Briefly, for adipogenic differentiation, cells were cultured for 14 days in AdipoDiff medium (Miltenyi Biotec) and stained with Oil red O (Sigma) following fixation. For osteogenic differentiation, cells were cultured in osteogenesis induction medium (see Supplementary Materials and Methods) for 21 days and calcium depositions were visualized by alizarin red staining (Sigma). Chondrogenic differentiation was induced by culturing cell pellets for 28 days in chondrogenesis-induction medium (see Supplementary Materials and Methods). Cryosections of fixed pellets were stained with goat anti-human aggrecan, and nuclei were stained with 4', 6-diamidino-2-phenylindole (DAPI; Life Technologies). Sections were analyzed with an Axiovert 200 M fluorescence microscope equipped with an AxioCam HRm camera (both from Carl Zeiss).

In vivo transplantation

For primary in vivo transplantations, sorted lin\(^{-}\)/CD45\(^{-}\)/CD271\(^{+}\)/CD140a\(^{-}\) cells were expanded under non-adherent and adherent conditions. Spheres and colonies, respectively, were generated both from bulk sorted cells seeded at clonal densities and from single sorted cells. After expansion, cells were harvested and loaded overnight on hydroxyapatite/tricalcium phosphate ceramic powder (HA/TCP; Triosite, Zimmer) and then implanted s.c. into 8-week-old NOD.Cg-Prkdcsid1Brlm1Wjl/SJ (NSG) mice.

To evaluate in vivo self-renewal, implants were removed after 8 weeks, digested in 0.25% type I collagenase (STEMCELL Technologies) for 2 h at 37\(^{\circ}\)C, and the harvested cells were stained with anti-mouse CD45 and anti-human CD90 and CD105 antibodies for FACS sorting. CD45\(^{+}\)CD90\(^{+}\)CD105\(^{+}\) sorted live cells (7AAD exclusion) were plated at clonal density for sphere and CFU-F colony formation. Spheres and CFU-Fs were enumerated after 10 and 14 days, respectively, and further expanded for secondary transplantations.

To assess the in vivo differentiation capacities, implants were removed after 8 weeks after primary and secondary sections were either stained with hematoxylin/eosin and analyzed as described [9] or prepared for immunohistochemistry as described below. The animal procedures were approved by the local ethics committee on animal experimentation.

Immunohistochemistry

Paraffin-embedded implanted samples were cut into 5 \(\mu\)m thick sections. Sections were deparaffinized and rehydrated following standard protocols [6]. Following antigen retrieval and blocking, sections were stained with primary antibodies (anti-vimentin, anti-mitochondria, and anti-CD45) and secondary antibodies followed by signal visualization (EnVision labeled polymer HRP; Dako) and microscopic examination using an Axiovert 200 M fluorescence microscope equipped with an AxioCam HRm camera (both from Carl Zeiss).
Olympus camera (BX51) and the cellSens Dimension software (Olympus). Details of the staining procedure are provided in the Supplementary Materials and Methods.

Quantitative RT-PCR

RNA from sorted CD90pos/CD105pos, CD90neg/CD105neg, and mouse CD45pos cells recovered from implants after primary transplantation was isolated from four individual donors. cDNA was synthesized, and quantitative real-time PCR analysis was performed (for more details, see Supplementary Materials and Methods).

Single-cell real-time PCR (Fluidigm)

Primary BM-MNCs were sorted based on the expression of CD271 and CD140a. Linneg/CD45neg/CD271pos/CD140alow/neg and Linneg/CD45neg/CD271pos/CD140aneg single cells were sorted directly into lysis buffer containing low EDTA TE buffer (Teknova), NP-40 (Sigma), and SUPERaseIn (Life Technologies). cDNA synthesis of single cells was performed using the qScript cDNA SuperMix Kit (Quanta Bioscience). Specific Target Amplification of 48 genes of interest (genes are listed in Supplementary Table S1) was carried out using the TATAt PreAmp GrandMaster Mix Kit (TATAt Biocenter) and the final product underwent exonuclease treatment (Exonuclease I Kit; New England Biolabs). The samples were mixed with EvaGreen Supermix-low ROX (Bio-Rad) and DNA binding dye and loading reagent (both from Fluidigm), loaded onto the 48.48 Dynamic Array IFC chip, and run on the BioMark™ (Fluidigm) system. Data analysis was performed using the BioMark Real-Time PCR Analysis and Singular Analysis Toolset software (Fluidigm). The grouping of the genes as presented in the violin plot analysis was based on published information on gene functions.

Statistical analysis

Data are expressed as mean ± standard deviation (mean ± SD). Student’s t-test and ANOVA were used for statistical analysis.

Results and Discussion

Phenotypical and sphere-forming properties of primary CD271pos/CD140alow/neg BMSCs

In the last years, considerable progress has been made in the identification of human primary BMSC markers [3,5]. We have previously reported that linneg/CD45neg/CD271pos/CD140alow/neg human bone marrow cells (hereinafter referred to as CD271pos/CD140alow/neg cells) represented a close to pure population of stromal progenitor cells [6].

As reported, freshly-sorted CD271pos/CD140alow/neg cells showed typical morphological BMSC features (Fig. 1A) [2,10] and expressed a typical “mesenchymal” stromal cell (MSC) surface marker profile (Fig. 1B) [5,6,11]. Expression of CD56, which was reported to identify bone-lining BMSCs [5], was limited to a small fraction of the cells (Fig. 1B). Thus, CD56 might be a possible positive marker for endosteal niche BMSCs, complementary to the negative expression of CD146 that we previously reported for this cell population [2]. Expression of integrin z6 (CD49f) on cultured MSC has been implicated in enhancing stem cell properties [12]. Interestingly, CD49f was clearly expressed in about one third of the CD271pos/CD140alow/neg cells (Fig. 1B), which might indicate a possible role of CD49f in maintaining stemness of primary BMSCs. Certainly, this is an interesting point that will be addressed in future experiments.

Gene expression profiling of prospectively enriched BMSC has been reported for bulk sorted cells [6,13,14], which has obvious limitations when aiming to characterize highly-purified BMSCs. We therefore investigated the expression of a panel of selected BMSC-relevant genes in single-sorted CD271pos/CD140alow/neg cells (Fig. 1C, D and Supplementary Table S1).

CD271pos/CD140alow/neg cells showed a high and homogeneous expression of CXCL12 and ANGPT (Fig. 1D, group I), the majority of common MSC-related genes (group II), most of the differentiation genes (group III), as well as Wnt signaling pathway-related genes (group VI), which are in accordance with published data on bulk sorted cells [13,14]. Interestingly, IL-7 expression was heterogeneous (group I), which might point to a differential function of BMSC subsets in bone marrow lymphopoiesis. Furthermore, variances in expression of chondrocyte differentiation marker SOX9 (Fig. 1D, group III) are likely to reflect differentiation potential differences. Low expression levels were observed for NES (group II), SOX10 (group V), as well as several group IV and VI genes. Finally, CD271pos/CD140alow/neg cells clearly formed a distinct population as identified by principal component analysis compared with the non-CFU-F-containing CD271neg cells (Fig. 1E).

In vitro, CD271pos/CD140alow/neg cells formed typical spheres (Fig. 2A) and CFU-F (not shown), the latter being the standard classical assay for clonogenic BM stromal cells. Progenitor cell frequencies of sorted CD271pos/CD140alow/neg BMSCs were comparable in both assays (Fig. 2B), and crossover replating experiments demonstrated that spheres and CFU-Fs had similar capacities to form secondary and tertiary CFU-Fs and spheres, respectively (Fig. 2C). Furthermore, CD271pos/CD140alow/neg -derived spheres exhibited a typical surface marker profile and in vitro differentiation pattern (Fig. 2D,E), and increasing sphere numbers in vitro were observed up to the second passage (Fig. 2F), which was comparable to standard CFU-F cultures (Fig. 2G).

Taken together, these data indicate that CD271pos/CD140alow/neg cells represent a highly enriched population of BMSCs with phenotypical stroma cell properties and in vitro mesospheres-forming capacity.

In vivo stem cell functions of CD271pos/CD140alow/neg BMSCs

Previous reports demonstrated in vitro stem/progenitor cell properties of human BMSCs [15,16]. However, true stem cell properties cannot be assessed in vitro, but only in vivo by proving that a putative stem cell can generate cells that are functionally equivalent to the original.

Evidence that primary BMSCs are stem cells comes from seminal studies demonstrating that single CFU-F-derived clonal cells were capable of generating bone and hematopoietic stroma in vivo and that secondary CFU-F could be recovered from the transplants [1]. Furthermore, in vivo self-renewal of clonogenic cells was demonstrated for fetal human and adult murine BMSCs using the mesospheres assay [8,17]. However, whether or not adult human BMSCs fulfill stringent stem cell criteria in a serial transplantation setting has not been thoroughly addressed thus far, although...
FIG. 2. In vitro potential of lin<sup>neg</sup>/CD45<sup>neg</sup>/CD271<sup>pos</sup>/CD140<sub>a</sub><sup>low/neg</sup> human bone marrow stromal cells. (A) CD271<sup>pos</sup>/CD140<sub>a</sub><sup>low/neg</sup> BMSCs were sorted and assayed as spheres. The morphology of typical spheres is shown in (A) (scale bar indicates 200 μm). (B) Frequencies of CFU-F and spheres in bulk-sorted lin<sup>neg</sup>/CD45<sup>neg</sup>/CD271<sup>pos</sup>/CD140<sub>a</sub><sup>low/neg</sup> cells were comparable (data are presented as mean ± SD, n = 6). (C) Sorted lin<sup>neg</sup>/CD45<sup>neg</sup>/CD271<sup>pos</sup>/CD140<sub>a</sub><sup>low/neg</sup> cells were assayed in standard adherent culture as CFU-F and as sphere colonies in sphere cultures. CFU-F and sphere colonies were then harvested and replated under both, CFU-F and sphere conditions, for two additional passages. Data are given for individual experiments with spheres and CFU-F indicated by circles (○) and triangles (Δ), respectively. Arrows used in the x-axis labels indicate switch to the next culture condition, for example, “sph→CFU-F→sph” indicates that cells initially cultured under sphere conditions were recultured as CFU-F, and finally cultured as tertiary colonies under sphere conditions. (D) Spheres showed a typical MSC surface marker profile; a representative set of data with passage 3 cells of a total of three experiments is shown. Blue line: spheres; red line: corresponding isotype control. (E) Trilineage in vitro differentiation potential of CD271<sup>pos</sup>/CD140<sub>a</sub><sup>low/neg</sup> BMSC-derived spheres. A representative set of pictures from a total of three experiments with passage 2 cells is shown; scale bars represent 100 μm (adipocyte) and 200 μm (osteoblast and chondrocyte). (F) CD271<sup>pos</sup>/CD140<sub>a</sub><sup>low/neg</sup> BMSC-derived spheres were harvested and replated up to four times. A net increase of sphere numbers was observed for the first and second passages, respectively. Data are presented as -fold change from three independent experiments indicated by different symbols. (G) CD271<sup>pos</sup>/CD140<sub>a</sub><sup>low/neg</sup> BMSC-derived CFU-Fs were harvested and replated up to four times. Data are presented as -fold change from four independent experiments indicated by different symbols. Sph, spheres.
this is an important aspect when characterizing the nature and function of primary native BMSCs.

We therefore short-term expanded single-cell and bulk-sorted CD271\textsuperscript{pos}/CD140\textsubscript{a}^\textsuperscript{low/neg} BMSCs as spheres followed by subcutaneous implantation into immunodeficient mice (Fig. 3A). After 8 weeks, implants were harvested, assayed for human spheres, and then retransplanted into secondary recipients. FACS-isolation of human transplanted cells was performed based on the expression of human CD90 and CD105 (Supplementary Fig. S2A). CD90 and CD105 were chosen as sorting markers because of their relative stable expression in the transplanted cells in contrast to other markers. The sorting strategy and detection approach were validated by qPCR analysis of human and mouse housekeeping genes (Supplementary Fig. S2B).

In vivo self-renewal of CD271\textsuperscript{pos}/CD140\textsubscript{a}^\textsuperscript{low/neg} BMSCs was demonstrated by increasing number of spheres after primary and secondary transplantation compared with pre-transplantation values for both bulk-sorted (1.16 ± 0.06 and 2.34 ± 0.13-fold, respectively, \( n = 3 \)) and single cell-derived spheres (1.54 ± 0.28 and 2.51 ± 0.72-fold, \( n = 3 \)) (Fig. 3B and Supplementary Table S2). In contrast, implantation of adherently cultured CFU-Fs resulted in a more than 100-fold reduction of colony numbers after primary transplantation (Supplementary Fig. S2C), and therefore, secondary CFU-F transplantations were not performed.

In addition to in vivo sphere self-renewal, CD271\textsuperscript{pos}/CD140\textsubscript{a}^\textsuperscript{low/neg} BMSCs demonstrated serial in vivo differentiation capacity. Transplanted spheres generated human bone, adipocytes, and stromal tissues after primary and secondary implantation, with murine hematopoietic cells invading the implants (Fig. 3C, D, respectively). There is cumulating evidence that differentiation potentials differ between stromal cells depending on their tissue of origin [18–20]. Our current work focused on BMSC and it therefore remains to be investigated whether or not stromal cell preparations from other sources have similar sphere formation and serial in vivo transplantation capacities.

Taken together, these results indicate that primary CD271\textsuperscript{pos}/CD140\textsubscript{a}^\textsuperscript{low/neg} BMSCs are capable of in vivo self-renewal and differentiation. Cultures, which contained growth factors and prevented adherence to plastic, but not standard

**FIG. 3.** In vivo self-renewal and differentiation capacity of lin\textsuperscript{neg}/CD45\textsuperscript{neg}/CD271\textsuperscript{pos}/CD140\textsubscript{a}^\textsuperscript{low/neg} human bone marrow stromal cells. (A) Lin\textsuperscript{neg}/CD45\textsuperscript{neg}/CD271\textsuperscript{pos}/CD140\textsubscript{a}^\textsuperscript{low/neg} cells were sorted (bulk and single cell) and tested for in vivo self-renewal and differentiation as depicted in the schematic drawing. CD271\textsuperscript{pos}/CD140\textsubscript{a}^\textsuperscript{low/neg} -derived spheres (or CFU-Fs) were injected s.c. into NSG mice, explanted, sorted for human cells, analyzed, and retransplanted. Following another 8 weeks after secondary transplantation, cells were sorted again based on the expression of human-specific markers and analyzed (A). As shown in (B), bulk and single cell-derived spheres from sorted CD271\textsuperscript{pos}/CD140\textsubscript{a}^\textsuperscript{low/neg} cells clearly demonstrated in vivo self-renewal indicated by increased numbers of total spheres after primary and secondary transplantations (data are given as mean ± SD, \( n = 3 \), **\( P < 0.01 \), and ***\( P < 0.001 \)). In contrast, numbers of CD271\textsuperscript{pos}/CD140\textsubscript{a}^\textsuperscript{low/neg} -derived CFU-F decreased after primary transplantation (Supplementary Fig. S2C). (C, D) Formation of ectopic tissues following primary and secondary transplantations of spheres derived from CD271\textsuperscript{pos}/CD140\textsubscript{a}^\textsuperscript{low/neg} cells. Spheres were implanted subcutaneously with HA carrier into NSG mice. Representative sections 8 weeks after primary and secondary transplantation are shown in (C) and (D), respectively. The photomicrographs in the upper row left demonstrated generation of bone (b), adipocytes (a), and stromal tissues (Hematoxylin eosiin staining, HE). Dark brown areas represent HA/TCP particles. Immunohistochemical staining with anti-human vimentin (upper row, right), anti-human mitochondria (lower row, left), and anti-mouse CD45 antibodies (lower row, right) indicates human and murine origin of the stromal tissues and hematopoietic cells, respectively. Scale bars represent 100 \( \mu \)m for HE and anti-CD45 staining, and 50 \( \mu \)m for anti-vimentin and anti-mitochondria staining. For controls, see Supplementary Figure S2D.
adherent cultures, enhanced stem cell properties and allowed to expand transplantable stromal stem cells, which is certainly an important finding for future studies aiming to design stroma stem cell replacement and repair strategies.

Acknowledgments

This work was supported by funds from the HematoLinné and Stem Therapy Program, the Swedish Cancer Foundation, the Swedish Childhood Cancer Foundation, Gunnar Nilsson’s Cancer Foundation, Gunnel Björk’s Testament, ALF (Government Public Health Grant), and the Skåne County Council’s Research Foundation. The authors thank Helene Larsson and Anna Jonasson for help with the bone marrow samples, the Lund Stem Cell Center FACS facility for excellent technical assistance, and Dr. Simón Méndez-Ferrer (Wellcome Trust-Medical Research Council Cambridge Stem Cell Institute and NHS Blood and Transplant, Cambridge, United Kingdom) for critical discussions.

Author Disclosure Statement

The authors have no conflicts of interest to disclose.

References


Address correspondence to:
Stefan Scheding, MD
Division of Molecular Hematology
Department of Laboratory Medicine
University of Lund
BMC B12, Klinikgatan 26
Lund 22184
Sweden

E-mail: stefan.scheding@med.lu.se

Received for publication June 10, 2016
Accepted after revision August 12, 2016
Prepublished on Liebert Instant Online August 12, 2016
Supplemental Materials and Methods

Antibodies

For FACS analysis and cell sorting the following antibodies were used: CD34-APC (clone 581), CD56-APC (clone B159), CD105-APC (clone 266), CD90-APC (clone 5E10), CD140a-PE (clone αR1), CD73-PE (clone AD2), HLA-ABC-PE (clone G46-2.6), HLA-DR-FITC (clone Tu39), CD45-FITC (clone 2D1), CD45-APC-Cy7 (clone CE) (all from BD Bioscience, Erembodegem, Belgium), CD271-FITC and CD271-APC (clone ME20.4-1.H4), SUSD2-APC (clone W5C5), CD49f-APC (clone GoH3), CD140b-APC (REA363), CD151-APC (clone REA265) (all from Miltenyi Biotec, Bergisch Gladbach, Germany), LEPR-APC (clone 52263) (R&D Systems, Abingdon, United Kingdom), CD31-APC (clone WM59, Biolegend, San Diego, USA). Matched isotype controls were from BD Bioscience and R&D Systems. Chondrocyte pellet cryo sections were stained with anti-human aggrecan (R&D Systems, Abingdon, United Kingdom) followed by secondary antibody staining with donkey anti-goat IgG-Texas Red (Jackson ImmunoResearch Laboratories, Baltimore, USA). For the immunohistochemistry studies, anti-vimentin (clone SP20) (Thermo Scientific, Runcorn, United Kingdom), anti-mitochondria (clone 113-1) (Millipore, Temecula, USA) and anti-CD45 (clone 10558) (Abcam, Cambridge, United Kingdom) antibodies were used.

Flow cytometry analysis

Freshly isolated RosetteSep-depleted BM-MNCs were stained with directly-conjugated antibodies (30 min, 4°C) after blocking of unspecific binding using blocking buffer (PBS with 1% fetal bovine serum (Gibco) and 3.3 mg/ml human immunoglobulin
Cells were analyzed on a LSR II flow cytometer (BD) and data were analyzed using the FlowJo software (Tree star, USA). Adherently-cultured cells were harvested with 0.05% Trypsin-EDTA (GE HyClone, Logan, USA), whereas nonadherent sphere-cultured cells were digested with 0.25% type I collagenase (StemCell Technologies, Grenoble, France) to prepare single cell suspensions. Non-specific binding was blocked by using blocking buffer (see above), and cells were stained with the following directly-conjugated antibodies: anti-HLA-DR-FITC, anti-CD34-APC, anti-CD73-PE, anti-HLA-ABC-PE, anti-CD140a-PE, anti-CD105-APC, anti-CD90-APC, anti-CD271-APC and anti-CD31-APC. Matched isotype controls were all from BD Biosciences. Dead cells were excluded by 7-AAD (1 μg/ml, Sigma) staining. Samples were analyzed on a FACS Calibur (BD Biosciences) and data analysis was performed using the FlowJo software.

**Mesensphere growth medium**

The sphere growth medium used in this study contained the following components as described before[1,2]: 15% chicken embryo extract (CEE), 0.1 mM β-mercaptoethanol (Sigma), 1% non-essential amino acids, 1% antibiotic-antimycotic solution (Sigma), 1% N2 supplement, 2% B27 supplement (Invitrogen), recombinant human oncostatin (20 ng/ml, Invitrogen), recombinant human epidermal growth factor (EGF, 20 ng/ml, Invitrogen), recombinant human fibroblast growth factor (FGF)-basic (20 ng/ml, Invitrogen), recombinant human platelet-derived growth factor (PDGF-AB) (20 ng/ml, Peprotech, Stockholm, Sweden) and recombinant human insulin-like growth factor-1 (IGF-1) (40 ng/ml, Invitrogen) in DMEM/F12 (1:1)/human endothelial serum-free medium (1:2) (Invitrogen). CEE was prepared as described previously.[3]
CFU-F assays

Sorted BM-MNCs were cultured in standard MSC culture medium [StemMACS MSC Expansion Medium (Miltenyi Biotec, Bergisch Gladbach, Germany) plus 1% antibiotic-antimycotic solution (Sigma)]. Medium was changed weekly and passaged as described[4]. To evaluate the CFU-F frequency of BM-MNC populations, lin<sup>neg</sup>/CD45<sup>neg</sup>/CD271<sup>pos</sup>/CD140a<sup>low/neg</sup> FACS-sorted cells were cultured at plating densities of 1-10 cells/cm<sup>2</sup> in standard MSC medium. On day 14, cells were fixed with methanol and stained with 1% Crystal Violet (Sigma). Colonies containing ≥ 40 fibroblast-like cells were counted as CFU-F. Assays were set up in triplicates. For expansion of single cell-derived CFU-F, lin<sup>neg</sup>/CD45<sup>neg</sup>/CD271<sup>pos</sup>/CD140a<sup>low/neg</sup> cells were directly sorted into 96-well plates containing standard MSC medium. After three weeks, cells were harvested using Trypsin-EDTA, and passaged for continued culture for use in the subsequent experiments.

Osteogenesis and chondrogenesis growth medium

Induction media for osteogenesis and chondrogenesis were composed as described previously [4,5]. Osteogenesis growth medium contained DMEM high glucose/L-glutamine (Invitrogen), with β-glycerophosphate (Sigma), L-ascorbic acid-2-phosphate (Wako, Neuss, Germany) and dexamethasone (Sigma). The chondrogenesis-induction contained medium DMEM high glucose/L-glutamine (Invitrogen) with L-ascorbic acid-2-phosphate, L-proline (Sigma), pyruvic acid sodium salt (Sigma), ITS+ culture supplement (BD Biosciences) and TGF-β3 (R&D systems).
**Immunohistochemistry**

Heat-induced antigen retrieval was performed using Target Retrieval solution (Dako) for 30 minutes at 98°C. Endogenous peroxidase activity was quenched with peroxidase-blocking solution (Dako). Sectioned were blocked and stained for 1 hour at room temperature with primary antibodies (anti-vimentin, anti-mitochondria, anti-CD45). After washing, secondary staining with peroxidase labelled polymer conjugated to goat anti-mouse and goat anti-rabbit immunoglobulins was performed for 1 hour at room temperature and signal was visualized with EnVision Dual Link System-HRP (Dako). Nuclei were counterstained with hematoxylin and sections were mounted with Pertex (Histolab, Gothenburg, Sweden) mounting medium for microscopic analysis.

**Quantitative RT PCR**

cDNA was synthesized by Transcriptor first strand cDNA synthesis kit (Roche, Stockholm, Sweden) on C1000TM Thermal Cycler (Bio-Rad, Hercules, CA, USA). Quantitative real-time PCR analysis was carried out using Fast SYBR master mix (Applied Biosystems by Life Technologies) according to manufacturer’s instructions. Primer sequences for hB2M gene was TGCTGTCTCCATGTTTGATGTATCT (forward) and TCTCTGCTCCACCTCCTAAGT (reverse) and for mGAPDH gene was CTGGAGAAACCTGCCAAGTA (forward) and TGTTGCTGTAGCCGTATTCA (reverse) (RealTimePrimers.com). The crossing point of each sample was measured with StepOne softwatre (Applied Biosystems). The crossing point of each sample was measured
and analyzed with StepOne Software v2.1 (Applied Biosystems). The expression of each mRNA was determined using the 2-ΔΔCT threshold cycle method.

Supplemental References


**Supplemental Table 1:** List of genes analyzed by single cells qRT-PCR (Fluidigm)

<table>
<thead>
<tr>
<th>Gene name and description</th>
</tr>
</thead>
<tbody>
<tr>
<td>ALPL: Alkaline phosphatases</td>
</tr>
<tr>
<td>LPL: Lipoprotein Lipase</td>
</tr>
<tr>
<td>ANGPT1: Angiopoietin1</td>
</tr>
<tr>
<td>NES: Nestin</td>
</tr>
<tr>
<td>BMP4: Bone Morphogenetic Protein 4</td>
</tr>
<tr>
<td>NGFR: Nerve Growth Factor Receptor</td>
</tr>
<tr>
<td>BMP5: Bone Morphogenetic Protein 5</td>
</tr>
<tr>
<td>PAX1: Paired Box1</td>
</tr>
<tr>
<td>BMP7: Bone Morphogenetic Protein 7</td>
</tr>
<tr>
<td>PAX2: Paired Box2</td>
</tr>
<tr>
<td>CDH11: Cadherin 11</td>
</tr>
<tr>
<td>PAX3: Paired Box3</td>
</tr>
<tr>
<td>CEBPA: Enhancer Binding Protein α</td>
</tr>
<tr>
<td>PAX8: Paired Box8</td>
</tr>
<tr>
<td>CXCL12: Chemokine (C-X-C Motif) Ligand 12</td>
</tr>
<tr>
<td>PDGFRA: Platelet-Derived Growth Factor Receptor β</td>
</tr>
<tr>
<td>EPHA4: Ephrin receptor A4</td>
</tr>
<tr>
<td>PPARG: PPARgamma</td>
</tr>
<tr>
<td>FABP4: Fatty Acid Binding Protein 4</td>
</tr>
<tr>
<td>RUNX2: Runt-Related Transcription Factor 2</td>
</tr>
<tr>
<td>FGFR3: Fibroblast Growth Factor Receptor 3</td>
</tr>
<tr>
<td>SFRP1: Secreted Frizzled-Related Protein 1</td>
</tr>
<tr>
<td>FRZB: Frizzled-Related Protein</td>
</tr>
<tr>
<td>SFRP4: Secreted Frizzled-Related Protein 4</td>
</tr>
<tr>
<td>FZD1: Frizzled Class Receptor 1</td>
</tr>
<tr>
<td>SNAI1: Snail Family Zinc Finger 1</td>
</tr>
<tr>
<td>FZD4: Frizzled Class Receptor 4</td>
</tr>
<tr>
<td>SNAI2: Snail Family Zinc Finger 2</td>
</tr>
<tr>
<td>FZD7: Frizzled Class Receptor 7</td>
</tr>
<tr>
<td>SOX10: SRY (Sex Determining Region Y)-Box 10</td>
</tr>
<tr>
<td>FZD9: Frizzled Class Receptor 9</td>
</tr>
<tr>
<td>SOX9: SRY (Sex Determining Region Y)-Box 9</td>
</tr>
<tr>
<td>GATA2: GATA Binding Protein 2</td>
</tr>
<tr>
<td>SPARC: Secreted Protein, Acidic, Cysteine-Rich (Osteonectin)</td>
</tr>
<tr>
<td>GHR: Growth Hormone Receptor</td>
</tr>
<tr>
<td>SPP1: Secreted Phosphoprotein 1</td>
</tr>
<tr>
<td>HAND1: Heart And Neural Crest Derivatives Expressed 1</td>
</tr>
<tr>
<td>TGFBR3: Transforming Growth Factor, Beta Receptor III</td>
</tr>
<tr>
<td>IGFBP3: Insulin-Like Growth Factor Binding Protein 3</td>
</tr>
<tr>
<td>VCAM1: Vascular Cell Adhesion Molecule 1</td>
</tr>
<tr>
<td>IL7: Interleukin 7</td>
</tr>
<tr>
<td>VEGFC: Vascular Endothelial Growth Factor C</td>
</tr>
<tr>
<td>JAG1: Jagged 1</td>
</tr>
<tr>
<td>WIF1: WNT Inhibitory Factor 1</td>
</tr>
<tr>
<td>LEPR: Leptin Receptor</td>
</tr>
</tbody>
</table>
**Supplemental Table 2:** Number of sorted cells and spheres used in the serial transplantation experiments.

<table>
<thead>
<tr>
<th>Bulk-sorted CD271&lt;sup&gt;pos&lt;/sup&gt;/CD140&lt;sub&gt;a&lt;sup&gt;low/neg&lt;/sub&gt;&lt;/sup&gt; BMSCs*</th>
<th>Implanted spheres*</th>
<th>Recovered spheres from primary tx* and implanted into secondary recipients</th>
<th>Recovered spheres from secondary tx</th>
</tr>
</thead>
<tbody>
<tr>
<td>500</td>
<td>65</td>
<td>71</td>
<td>160</td>
</tr>
<tr>
<td>500</td>
<td>70</td>
<td>82</td>
<td>154</td>
</tr>
<tr>
<td>500</td>
<td>83</td>
<td>102</td>
<td>196</td>
</tr>
</tbody>
</table>

**Transplantation of bulk-derived spheres**

*: data are presented as total number of cells and spheres, respectively. Each row represents the data from one individual experiment. tx, transplantation.

<table>
<thead>
<tr>
<th>Single-cell-sorted CD271&lt;sup&gt;pos&lt;/sup&gt;/CD140&lt;sub&gt;a&lt;sup&gt;low/neg&lt;/sub&gt;&lt;/sup&gt; BMSCs</th>
<th>Expanded and implanted spheres*</th>
<th>Recovered spheres from primary tx and implanted into secondary recipients</th>
<th>Recovered spheres from secondary tx</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>21</td>
<td>29</td>
<td>40</td>
</tr>
<tr>
<td>1</td>
<td>16</td>
<td>30</td>
<td>53</td>
</tr>
<tr>
<td>1</td>
<td>18</td>
<td>25</td>
<td>42</td>
</tr>
</tbody>
</table>

**Transplantation of single-cell-derived spheres**

Primary spheres were generated from single cell-sorted CD271<sup>pos</sup>/CD140<sub>a<sub>low/neg</sub></sup> cells (left column). In total, 150 cells were seeded individually of which 18 generated single cell-derived spheres. Single cell-derived spheres from three independent experiments were selected for primary transplantation based on the number of primary spheres. Each row represents the data from one individual experiment. *: data are presented as total number of cells and spheres, respectively. tx, transplantation.
Supplemental Figure 1. (A) FACS gating and analysis strategy. RosetteSep lineage-depleted bone marrow cells were stained with monoclonal antibodies as described. Following gating on forward/side scatter and doublet exclusion (upper panel), dead cells were excluded by gating on 7AAD<sup>−</sup> cells (left plot, lower panel) followed by gating on CD45<sup>−</sup> cells (middle plot, lower panel). Primary BMSC were then analyzed for co-expression of other markers and sorted, respectively by gating on the CD271<sup>+</sup>/CD140a low/neg population (right plot, lower panel). A representative set of FACS plots is presented. (B) Analysis and sorting gates were set according to fluorescence-minus one (FMO) controls as defined by isotype control staining. A representative set of FACS plots is presented.
Supplemental Figure 2. (A) Gating strategy for sorting of human cells recovered 8 weeks after primary and secondary transplantation of CD271^{pos}/CD140^{low/neg} -derived spheres and CFU-F, respectively. Human CD90^{pos}/CD105^{pos} cells were sorted following FSC/SSC gating (not shown), exclusion of murine CD45^{pos} cells (left plot), and dead cell exclusion (middle plot). Sorting gates were set according to empty HA/TCP (hydroxyapatite/tricalcium phosphate ceramic powder) controls, i.e. implants that did not contain human cells (right plot). FACS plots represent a representative set of data after primary transplantation of spheres. (B) qPCR analysis of freshly sorted hCD90^{pos}CD105^{pos}, hCD90^{neg}CD105^{neg} and mouse CD45^{pos} cells after secondary transplantation indicated the percentage of cells expressing human-specific beta 2 microglobulin, hB2M (data are presented as mean ± SD, n=4). (C) In contrast to sphere transplantation, numbers of CD271^{pos}/CD140^{low/neg} -derived CFU-F decreased after primary transplantation when compared to numbers of injected CFU-F (data are given as mean ± SD, n=3). (D) Empty implant controls (HA/TCP without cells) were stained with HE (hematoxylin and eosin). Immunohistochemistry staining of empty implant controls with antibodies against human mitochondria, human vimentin and mouse CD45 are shown in the photomicrographs. Scale bars represent 50 µm. Representative sections eight weeks after transplantation are shown.